Further Analysis From The ATHENA Study Showed That Multaq® Reduced The Risk Of Stroke In Patients With Atrial Fibrillation. The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. Previous results from the landmark ATHENA study have shown that the investigational medicine dronedarone on top of standard therapy decreased the combined primary endpoint of the risk of cardiovascular hospitalisations or death from any cause by a statistically significant 24% p=0.

Further Analysis From ATHENA Study Showed That Multaq Reduced The Risk Of Stroke In Patients With Atrial Fibrillation. This Analysis Showed That Multaq Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany.

Human Genome Sciences Reports Initial Results Of Randomized Phase 2 Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma. Human Genome Sciences, Inc. reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 in combination with bortezomib in patients with advanced multiple myeloma. The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination vs. bortezomib alone.

VCU Massey Cancer Center Spearheads Novel Clinical Study For Lymphoma Patients. The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute -sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma. The study is based on research from VCU Massey Cancer Center as well as other centers suggesting that combining two novel, recently approved drugs that have shown effectiveness in certain blood cancers may be active in patients with diffuse large B-cell lymphoma, or mantle cell lymphoma.

Anavex Completes Successful Preclinical Studies On Lead Alzheimer's Drug Candidate. Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System diseases and cancer, announced the successful completion of preclinical studies on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.

Results Of The APPRAISE-I Dose Guiding Trial. While the results of the study did not show a statistically significant difference in ischemic events among any of the four doses of apixaban evaluated, trends emerged that support further study, according to researchers at the Duke Clinical Research Institute. Apixaban targets the activity of Factor Xa, one of several enzymes involved in process of blood coagulation. The drug is just one of several new anti-clotting agents under development.

FDA staff note deaths in Pfizer bone drug study. Osteoporosis patients given a low dose of an experimental Pfizer Inc pill were more likely to die within five years than others who got a placebo, U.S. drug reviewers said in an analysis released on Thursday.

Advances In The Management Of Patients With Diabetes Mellitus. Disappointing results of latest treatments of blood glucose which have not convincingly reduced problems, apart from sub-clinical micro-vascular disease Current drugs offer little evidence that treatment of..

Lipitor 80 Mg Provided Sustained Risk Reduction Of Cardiovascular Events In Patients With Heart Disease During The Five-Year TNT Trial. Pfizer announced that in patients with established heart disease, Lipitor® 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets study.

Prasugrel Significantly Reduced New Or Recurrent Heart Attacks In Both Acute And Longer-Term Settings Following PCI, Compared With Clopidogrel. A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks 7.4 percent vs. 9.7 percent, p.

Back-to-school shoppers: Good shoes are important to your child's health. Unfortunately, it seems that many parents do not realize the importance of keeping their children in good-quality footwear in the correct size.

At 50, AARP Enters Its Golden Years. The late-night comedians love to needle AARP as the unflagging advance team for senility. They're the folks who send the dreaded membership invite when you hit 50, an otherwise sunny reminder that you're well on your way to that last roundup.

IE8 is memory hog, says researcher. Microsoft's latest version of Internet Explorer 8 requires more than double the memory of its main rival, Mozilla's Firefox, and spawns nearly six times the number of processor threads, a performance researcher..

Highlights. See today's special section, Page A24, for a guide to television coverage of the Republican National Convention.

CV Therapeutics Initiates Phase 1 Clinical Trial Of CVT-3619, A Novel Potential Treatment For Cardiometabolic Diseases. CV Therapeutics, Inc. announced that the company has enrolled the first patient in a Phase 1 trial of CVT-3619, a novel oral compound for potential treatment of cardiometabolic diseases. The U.S. Food and Drug Administration recently accepted the Company's investigational new drug application for CVT-3619, a partial A1 adenosine receptor agonist.

Viewers Flock to a Ritzy Zip Code; CNN's Obama Coverage Makes Cable News History. With the two-hour season debut of "Top Model" yet to come -- featuring the reality series's very first transgender contestant! -- execs at under-the-gun CW felt comfortable taking their necks out of the guillotine after a second night of encouraging numbers.

Manual treadmill vs. motorized treadmill: Which is better? I'd like to buy a treadmill. Would I get a better workout using a manual treadmill or a motorized treadmill? Mayo Clinic physical medicine and rehabilitation specialist Edward Laskowski, M.D., and colleagues..

Licensed Physical Therapist. NAME: Susan E. Davis AGE: 53 EDUCATION: I did undergraduate study in biology and then switched to physical therapy.

Global study shows telmisartan reduces outcome of cardiovascular death, heart attack or stroke. August 31, 2008 -- An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke..

La Traviata's' Double Play. For those who mourned the demise of the Washington National Opera's opening-night simulcast on the Mall, the company has come through with a walk-off home run.